Plant virus particles for delivery of antimitotic agents
Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma.
1. An anti-lymphoma virus particle, comprising a filamentous plant virus particle linked to an antimitotic agent, wherein the filamentous plant virus particle is a member of the Alphaflexiviridae family.
2. The anti-lymphoma virus particle of claim 1 , wherein the exterior surface of the plant virus particle has been PEGylated.
3. The anti-lymphoma virus particle of claim 1 , wherein the antimitotic agent is a dolastatin.
4. The anti-lymphoma virus particle of claim 3 , wherein the dolastatin is monomethyl auristatin E (MMAE).
5. The anti-lymphoma virus particle of claim 3 , wherein the dolastatin is valine-citrulline monomethyl auristatin E (vcMMAE).
6. The anti-lymphoma virus particle of claim 1 , wherein the antimitotic agent is covalently conjugated to the exterior of the plant virus particle.
7. The anti-lymphoma virus particle of claim 1 , wherein a targeting ligand is attached to the exterior of the plant virus particle.
8. The anti-lymphoma virus particle of claim 1 , wherein the filamentous plant virus particle is Potato Virus X.
9. The anti-lymphoma virus particle of claim 8 , wherein the anti-mitotic agent is valine-citrulline monomethyl auristatin E (vcMMAE).
10. A method of treating lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-lymphoma virus particle, the anti-lymphoma virus particle comprising a filamentous plant virus particle linked to an antimitotic agent, wherein the filamentous plant virus particle is a member of the Alphaflexiviridae family.
11. The method of claim 10 , wherein the lymphoma is non-Hodgkin's lymphoma.
12. The method of claim 10 , wherein the anti-lymphoma virus particle is administered together with a pharmaceutically acceptable carrier.
13. The method of claim 10 , wherein the antimitotic agent is a dolastatin.
14. The method of claim 13 , wherein the dolastatin is MMAE.
15. The method of claim 13 , wherein the dolastatin is vcMMAE.
16. The method of claim 10 , wherein the antimitotic agent is covalently conjugated to the exterior of the plant virus particle.
17. The method of claim 10 , wherein a targeting ligand is attached to the exterior of the plant virus particle.
18. The method of claim 10 , wherein the filamentous plant virus particle is Potato Virus X.
19. The method of claim 18 , wherein the anti-mitotic agent is valine-citrulline monomethyl auristatin E (vcMMAE).